---
title: "Citi: Raises Pharmaron target price to HKD 28.8, maintains \"Outperform\" rating"
description: "Citi released a research report stating that Pharmaron (03759) has raised its revenue growth guidance for 2025 from a year-on-year increase of 10% to 15% to 12% to 16%, and expects adjusted net profit"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/263667131.md"
published_at: "2025-10-31T06:12:04.000Z"
---

# Citi: Raises Pharmaron target price to HKD 28.8, maintains "Outperform" rating

> Citi released a research report stating that Pharmaron (03759) has raised its revenue growth guidance for 2025 from a year-on-year increase of 10% to 15% to 12% to 16%, and expects adjusted net profit under International Financial Reporting Standards to achieve double-digit growth. The bank believes that the upward guidance and increased order backlog for Pharmaron from the end of this year to next year are encouraging. Citi has raised its revenue and net profit forecasts for Pharmaron for 2025 to 2027, with the target price for H shares increased from HKD 24.7 to HKD 28.8, and the target price for A shares raised from RMB 34.8 to RMB 40.6, maintaining an "Outperform" rating

According to the Zhitong Finance APP, Credit Lyonnais released a research report stating that Pharmaron (03759, 300759.SZ) has raised its revenue growth guidance for 2025 from a year-on-year increase of 10% to 15% to 12% to 16%, and expects adjusted net profit under non-International Financial Reporting Standards to achieve double-digit growth. The bank believes that Pharmaron's upward guidance and increased order backlog are encouraging for the end of this year and into next year. Credit Lyonnais has raised its revenue and net profit forecasts for Pharmaron for 2025 to 2027, with the target price for H-shares increased from HKD 24.7 to HKD 28.8, and the target price for A-shares raised from RMB 34.8 to RMB 40.6, maintaining an "outperform" rating

### Related Stocks

- [300759.CN - Pharmaron](https://longbridge.com/en/quote/300759.CN.md)
- [03759.HK - PHARMARON](https://longbridge.com/en/quote/03759.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Pharmaron To Raise HK$1.3 Billion in Share Placement | Pharmaron Beijing Co Ltd :SAYS IT PLANS TO PLACE 58.4 MILLION NEW H-SHARES AT HK$22.82 PER SHARESAYS IT EXPECTS TO RAISE | [Link](https://longbridge.com/en/news/272620883.md) |
| Pharmaron Beijing Announces Private Placement of 58 Million New H Shares | Pharmaron Beijing Co. Ltd. has announced a private placement of 58,440,762 new H shares under its general issuance manda | [Link](https://longbridge.com/en/news/272610619.md) |
| TAV Airports FY Net Profit Shrinks To 2.82 Bln Lira YOY, Proposes To Pay Dividend At Gross 3.61 Lira Per Share, Announces 2026 Guidance | TAV Airports reported a FY net profit of 2.82 billion lira, down from 6.56 billion lira year-over-year. The company's re | [Link](https://longbridge.com/en/news/276201362.md) |
| Pharmaron Acquires Majority Stake in Biortus for RMB1.3 Billion | Pharmaron Beijing Co., Ltd. has acquired an 82.54% stake in Biortus for approximately RMB1.3 billion, making Biortus a s | [Link](https://longbridge.com/en/news/263101055.md) |
| Pharmaron Raises HK$1.32 Billion via H-Share Placement to Fund Capacity Expansion | Pharmaron Beijing Co., Ltd. has raised approximately HK$1.32 billion through the placement of 58,440,762 new H shares at | [Link](https://longbridge.com/en/news/273351963.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.